- Report
- February 2024
- 175 Pages
Global
From €4818EUR$5,000USD£4,144GBP
- Report
- January 2024
- 175 Pages
Global
From €4818EUR$5,000USD£4,144GBP
- Report
- June 2022
- 111 Pages
Global
From €4577EUR$4,750USD£3,937GBP
- Report
- September 2019
Global
From €5174EUR$5,370USD£4,451GBP
Zenpep is a brand of endocrine and metabolic disorder drugs used to treat a variety of conditions, including pancreatic exocrine insufficiency, cystic fibrosis, and short bowel syndrome. These drugs are designed to replace or supplement the enzymes that the body is unable to produce, allowing the body to better absorb and digest food. Zenpep is a combination of three enzymes: pancrelipase, protease, and lipase. These enzymes are essential for the digestion of fats, proteins, and carbohydrates.
Zenpep is a popular choice for treating endocrine and metabolic disorders, as it is effective and well-tolerated. It is available in both capsule and powder form, and can be taken with or without food.
The Zenpep market is highly competitive, with many companies offering similar products. Some of the major players in the market include AbbVie, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more